Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Generic Competition (% pts cc): -6.0% in FY2025, down 4.0 pts from a year earlier.
Latest, FY2025
-6.0%
Period ended Dec 31, 2025
Change on a year earlier
-4.0 pts
-2.0% in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
“Net sales were USD 54.5 billion (+8%, +8% cc), with volume contributing 15 percentage points to growth. Generic competition had a negative impact of 6 percentage points, pricing had a negative impact of 1 percentage point and currency had no impact.”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K (Operating Review).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Generic Competition (% pts cc) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -6.0% | -4.0 pts | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | -2.0% | +2.0 pts | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2023 | Dec 31, 2023 | -4.0% | – | Novartis Form 6-K (0001370368-24-000007) ↗ |
Cite this data
StockData. (2026). Novartis Generic Competition (% pts cc) (%), annual FY2023–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/bridge-generic-pp
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.